See more : Max Metal Corporation Public Company Limited (MAX.BK) Income Statement Analysis – Financial Results
Complete financial analysis of CareDx, Inc (CDNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CareDx, Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Mission Ready Solutions Inc. (MSNVF) Income Statement Analysis – Financial Results
- EasTower Wireless Inc. (ETWLF) Income Statement Analysis – Financial Results
- Fujikon Industrial Holdings Limited (0927.HK) Income Statement Analysis – Financial Results
- Eros Media World Plc (ESGC) Income Statement Analysis – Financial Results
- SeqLL Inc. (SQLLW) Income Statement Analysis – Financial Results
CareDx, Inc (CDNA)
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 280.32M | 321.79M | 296.40M | 192.19M | 127.07M | 76.57M | 48.32M | 40.63M | 28.14M | 27.31M | 22.10M | 20.45M |
Cost of Revenue | 102.00M | 112.21M | 97.39M | 63.12M | 45.46M | 32.99M | 21.37M | 21.12M | 10.27M | 8.54M | 9.08M | 7.93M |
Gross Profit | 178.33M | 209.58M | 199.01M | 129.08M | 81.61M | 43.58M | 26.95M | 19.51M | 17.87M | 18.77M | 13.02M | 12.52M |
Gross Profit Ratio | 63.61% | 65.13% | 67.14% | 67.16% | 64.23% | 56.92% | 55.78% | 48.02% | 63.50% | 68.72% | 58.92% | 61.22% |
Research & Development | 81.87M | 90.39M | 76.53M | 48.94M | 30.71M | 14.51M | 12.39M | 12.39M | 9.33M | 3.85M | 3.18M | 4.75M |
General & Administrative | 117.87M | 100.40M | 74.96M | 48.81M | 36.54M | 21.96M | 18.91M | 20.73M | 12.25M | 8.44M | 4.81M | 4.69M |
Selling & Marketing | 83.33M | 96.03M | 77.25M | 53.86M | 38.89M | 21.67M | 12.81M | 11.17M | 8.35M | 6.47M | 5.89M | 5.42M |
SG&A | 201.20M | 196.42M | 152.21M | 102.66M | 75.43M | 43.63M | 31.72M | 31.89M | 20.60M | 14.91M | 10.70M | 10.11M |
Other Expenses | 98.62M | -2.87M | -2.63M | -4.81M | -719.00K | -178.00K | -1.49M | -1.92M | -188.00K | 147.00K | -536.00K | -14.00K |
Operating Expenses | 381.69M | 286.81M | 228.73M | 146.79M | 106.15M | 58.14M | 44.11M | 44.28M | 29.93M | 18.75M | 13.88M | 14.86M |
Cost & Expenses | 483.69M | 399.02M | 326.12M | 209.91M | 151.60M | 91.13M | 65.48M | 65.40M | 40.20M | 27.30M | 22.96M | 22.79M |
Interest Income | 11.87M | 3.76M | 160.00K | 271.00K | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 3.76M | 0.00 | 271.00K | 0.00 | 3.70M | 5.86M | 1.86M | 1.59M | 2.12M | 2.15M | 2.70M |
Depreciation & Amortization | 19.82M | 16.01M | 11.89M | 9.54M | 5.52M | 4.22M | 3.76M | 2.92M | 796.00K | 512.00K | 663.00K | 1.07M |
EBITDA | -89.66M | -61.22M | -17.84M | -10.21M | -19.01M | -11.36M | -14.61M | -17.85M | -11.26M | 523.00K | -194.00K | -1.27M |
EBITDA Ratio | -31.98% | -24.03% | -10.06% | -8.44% | -19.56% | -19.25% | -38.59% | -65.68% | -43.29% | -4.50% | -0.88% | -6.21% |
Operating Income | -203.36M | -77.23M | -29.73M | -17.72M | -24.53M | -15.58M | -20.29M | -37.33M | -11.93M | 1.25M | -857.00K | -2.34M |
Operating Income Ratio | -72.55% | -24.00% | -10.03% | -9.22% | -19.31% | -20.35% | -42.00% | -91.88% | -42.40% | 4.58% | -3.88% | -11.45% |
Total Other Income/Expenses | 13.22M | 997.00K | -2.36M | 2.78M | 585.00K | -32.64M | -36.98M | -4.03M | -1.78M | -1.97M | -2.69M | -2.72M |
Income Before Tax | -190.14M | -76.23M | -32.09M | -19.75M | -23.95M | -48.22M | -57.27M | -41.36M | -13.71M | -719.00K | -3.54M | -5.06M |
Income Before Tax Ratio | -67.83% | -23.69% | -10.83% | -10.28% | -18.85% | -62.97% | -118.51% | -101.80% | -48.70% | -2.63% | -16.03% | -24.74% |
Income Tax Expense | 141.00K | 379.00K | -1.43M | -1.04M | -1.98M | -1.43M | -1.71M | -1.61M | 665.00K | -1.50M | 2.15M | 2.70M |
Net Income | -190.28M | -76.61M | -30.66M | -18.71M | -21.97M | -46.76M | -55.47M | -39.47M | -13.71M | 781.00K | -3.54M | -5.06M |
Net Income Ratio | -67.88% | -23.81% | -10.34% | -9.74% | -17.29% | -61.06% | -114.79% | -97.14% | -48.70% | 2.86% | -16.03% | -24.74% |
EPS | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.13 | -0.48 | -0.69 |
EPS Diluted | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.10 | -0.48 | -0.69 |
Weighted Avg Shares Out | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.31M | 16.50M | 11.82M | 5.82M | 7.37M | 7.37M |
Weighted Avg Shares Out (Dil) | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.33M | 16.50M | 11.86M | 9.28M | 7.37M | 7.37M |
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
CareDx Reports Second Quarter 2023 Results
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
CareDx to Report Second Quarter 2023 Financial Results
CareDx's HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
CareDx's AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
Why Shares of CareDx Are Jumping Friday
Source: https://incomestatements.info
Category: Stock Reports